RCKT GC awarded 100,000 RSUs; holdings now 385,462 shares
Rocket Pharmaceuticals (RCKT) reported an insider equity award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rocket Pharmaceuticals (RCKT) reported an insider equity award. The company’s General Counsel acquired 100,000 shares on 11/03/2025 at a reported price of $0, identified as Restricted Stock Units that convert to common stock on a one-for-one basis and fully vest on 11/03/2026.
Following this transaction, the reporting person beneficially owned 385,462 shares, held directly. This filing reflects routine equity compensation rather than an open‑market purchase.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 100,000 | $0.00 | $0.00 |
Footnotes (2)
- F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
- F2. Represent RSUs that convert to common stock on a one-for-one basis. The RSUs will become fully vested on November 3, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did RCKT disclose in this Form 4?
Was this an open-market purchase or equity award for RCKT?
What is the vesting schedule for the RSUs at RCKT?
Who is the reporting person in RCKT’s Form 4?
How do the RSUs convert at RCKT?
AI-generated analysis. How Rhea-AI works. Not financial advice.